Abstract
Simple SummaryRadioligand therapy with [177Lu]PSMA-617 (PSMA-RLT) is a promising therapeutic option for metastatic castration-resistant prostate cancers (mCRPC), as its clinical relevance has recently been confirmed in the phase III VISION-trial. As prostate-specific antigen (PSA) plays an important role in the response evaluation of this therapy, and the aim of this study was to prospectively assess the prognostic value of early PSA measurements. We found PSA changes as early as four weeks after the first administration of PSMA-RLT to be predictive of both long-term biochemical and PET imaging response, as well as overall survival. We then evaluated relevant predictive thresholds in PSA change at that time point, as the early detection of long-term (non-)response to PSMA-RLT can be of great benefit in the clinical management of terminally ill mCRPC-patients.Purpose: Radioligand therapy with [177Lu]PSMA-617 (PSMA-RLT) is a promising therapeutic option for metastatic castration-resistant prostate cancer (mCPRP). This study assessed the prognostic value of early PSA measurements during PSMA-RLT. Methods: 27 patients with mCRPC scheduled for PSMA-RLT were prospectively enrolled for a serial short-interval PSA-assessment. Change in PSA (∆%PSA) during two treatment cycles was correlated with biochemical response (BR) and change in tumor volume on PET (TV) after 16 weeks (w16), as well as overall survival (OS). PCWG3 criteria and the recently recommended threshold of ∆%PSA ≤ −30% were assessed for their predictive value. Results: ∆%PSA first correlated with BR, TV and OS after 4 weeks (c1w4). At c1w4, ∆%PSA ≤ −30% was associated with the biochemical response at w16 (p = 0.003) and a longer median OS (p = 0.025), whereas the PCWG3-derived threshold of ∆%PSA ≤ −50% showed no such correlation. In contrast, ∆%PSA ≥ 25% at c1w4 was associated with biochemical progression at w16 (p = 0.003) and a shorter median OS (p < 0.001). Conclusion: PSA changes as early as four weeks after PSMA-RLT allow a significant prediction of later biochemical and PET-based imaging response, as well as OS. At this early time point, a more lenient threshold for a PSA decrease of at least 30% appears better-suited for the prediction of a positive biochemical response and longer OS. In contrast, the PCWG3-derived threshold for PSA increase (+25%) reliably anticipates biochemical progression and shorter OS.
Highlights
Prostate cancer comes in second place in both incidence and cause of all cancerrelated deaths for men worldwide [1]
Radionuclide therapy targeting the prostate-membrane specific antigen (PSMA)— a class II membrane glycoprotein frequently overexpressed by prostate cancer cells [2]— with 177Lu-labelled radioligands (PSMA radioligand therapy—PSMA-RLT) is a promising treatment [3–5], and its efficacy in the metastatic castration-resistant prostate cancer (mCRPC)-setting has recently been confirmed in the phase III VISION-trial [6]
The biochemical response status was confirmed in the prostate-specific antigen (PSA) follow-up. ∆%PSAw16 had no correlation to previous treatments or other relevant pretherapeutic parameters (p ≥ 0.15; Supplemental Table S2)
Summary
Prostate cancer comes in second place in both incidence and cause of all cancerrelated deaths for men worldwide [1]. Radionuclide therapy targeting the prostate-membrane specific antigen (PSMA)— a class II membrane glycoprotein frequently overexpressed by prostate cancer cells [2]— with 177Lu-labelled radioligands (PSMA radioligand therapy—PSMA-RLT) is a promising treatment [3–5], and its efficacy in the mCRPC-setting has recently been confirmed in the phase III VISION-trial [6]. Beside image-based assessment, the prostate-specific antigen (PSA) plays an important role as a biochemical marker in the evaluation of therapeutic response and clinical follow-up of prostate cancer [7]. In PSMA-RLT, the role of imaging with, for instance, CT or bone scans can be limited [8], as—in the case of diffuse or disseminated metastatic disease—the full extent of the disease may not be reflected, and bone scans may not change in appearance early on, despite progression or response. As well as clinical routine, changes in PSA are, frequently used to evaluate response to PSMA-RLT [3,4,10]. The PSA response is generally categorized in accordance with criteria recommended by the Prostate Cancer Working Group (PCWG)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call